Results 81 to 90 of about 53,515 (238)
Purpose To investigate the efficacy and safety of concurrent stereotactic radiosurgery (SRS) and ipilimumab or nivolumab in patients with untreated melanoma brain metastases.
Giuseppe Minniti +9 more
doaj +1 more source
ABSTRACT Dedifferentiated liposarcoma (DDLPS) is a rare soft tissue sarcoma with limited real‐world epidemiologic data. This nationwide retrospective study describes the epidemiology, management, and outcomes of DDLPS in France using the NETSARC+ national sarcoma registry.
Julien Bollard +23 more
wiley +1 more source
On the 15 November 2018, the Committee for Medicinal Products for Human Use adopted an extension to an existing indication for the use of nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for the first-line treatment of adult patients with ...
Jorge Camarero +12 more
doaj +1 more source
Use of ipilimumab in the treatment of melanoma
Utkarsh H Acharya, Joanne M Jeter Department of Medicine, Division of Hematology-Oncology, University of Arizona Cancer Center, Tucson, AZ, USA Abstract: Ipilimumab is a monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4 that has been ...
Acharya UH, Jeter JM
core
Ipilimumab: A Novel Treatment for Metastatic Melanoma
Objective: To review the mechanism of action, pharmacokinetics, efficacy, safety, drug interactions, dosing, and economic considerations of ipilimumab.
Morgan E Culver +3 more
core +1 more source
A Case of Ipilimumab Induced Hypophysitis [PDF]
Introduction Ipilimumab (Yervoy®) is a human monoclonal antibody that has been shown to significantly improve survival in cases of metastatic melanoma.1 Ipilimumab blocks cytotoxic T-lymphocyte antigen 4 (CTLA-4), a protein receptor on the surface of T ...
Ukrainski, MD, Melinda +3 more
core +1 more source
Alopecia Areata in a Patient Receiving Cemiplimab for Metastatic Cutaneous Squamous Cell Carcinoma
ABSTRACT Alopecia areata (AA) is an autoimmune disease characterized by non‐scarring hair loss of the scalp and/or body, with an unpredictable and variable clinical course. Its etiology is not entirely understood, although evidence suggests that environmental, immunological, and genetic factors contribute to disease development.
Marco Rubatto +7 more
wiley +1 more source
Cutaneous Eruptions Associated With Tumour Infiltrating Lymphocyte Therapy: A Case Series
ABSTRACT Tumour‐infiltrating lymphocyte (TIL) therapy is a newly emerged effective treatment for advanced melanoma refractory to immune checkpoint inhibitors; however, its cutaneous adverse effects remain uncharacterized. We present the first case series describing dermatologic adverse effects associated with TIL therapy for malignant melanoma in five ...
Shannon C. Lyden +9 more
wiley +1 more source
In this study, mean lung dose (MLD) and age were associated with an increased risk of treatment‐related pneumonitis in patients receiving concurrent chemoradiotherapy and immunotherapy, providing a reference for revising lung dose constraints. Abstract Objective Combining immune checkpoint inhibitors (ICIs) with chemoradiotherapy is being actively ...
Ying Lu +9 more
wiley +1 more source
IPILIMUMAB IN THERAPY OF METASTATIC MELANOMA [PDF]
Metastatic melanoma remains a refractory disease. Great progress in therapy of metastatic melanoma patients has been made in the recent five years. Targeted immunotherapy – a selective effect on lymphocytes signal molecules - became a principally new ...
I. V. SAMOILENKO +2 more
core +1 more source

